NCT03793166 2026-03-18
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
13 trialsNCT05092958 2026-03-18
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT07227402 2026-03-16
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07011719 2026-03-13
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT07405164 2026-02-12
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Not yet recruiting
NCT04446117 2025-12-18
CONTACT-02
Exelixis
Phase 3 Active not recruiting
NCT03937219 2025-09-10
COSMIC-313
Exelixis
Phase 3 Active not recruiting
NCT03141177 2025-06-06
CheckMate 9ER
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04338269 2025-04-04
CONTACT-03
Hoffmann-La Roche
Phase 3 Completed
NCT06364631 2025-01-16
CARE1
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT03729245 2023-04-11
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
Nektar Therapeutics
Phase 3 Terminated
NCT01865747 2021-04-27
METEOR
Exelixis
Phase 3 Completed
NCT01522443 2018-05-23
COMET-2
Exelixis
Phase 3 Terminated